Verrica Pharmaceuticals VRCA 深 沪
等待开盘 12-17 09:30:00 美东时间
8.60
+1.040
+13.76%
华盛通- 最 高8.92
- 今 开7.42
- 成交量 28.54万股
- 最 低 7.23
- 昨 收 7.56
- 总市值 8123.39万
- 52周最高 9.8212
- 市盈率 静 --
- 换手率 3.02%
- 52周最低 3.28
- 委 比 -94.78%
- 总股本 944.58万
- 历史最高 232.90
- 量 比 1.46
- 振 幅 22.35%
- 历史最低 3.816
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
12-16 20:05
Verrica Pharmaceuticals Secures $50M Financing Deal
Verrica Pharmaceuticals ( ($VRCA) ) has shared an announcement. On November 23,...
11-25 00:59
Verrica Pharmaceuticals announces $50M PIPE financing
Verrica Pharmaceuticals (VRCA) said it has signed securities purchase agreements for a private investment in public equity (PIPE) that will raise about $50 million in gross proceeds before fees. The f...
11-24 21:40
Verrica Pharmaceuticals shares are trading higher after the company announced a $50 million private placement to retire debt and extend its cash runway.
Verrica Pharmaceuticals shares are trading higher after the company announced a...
11-24 21:01
Verrica Pharmaceuticals Q3 Adj. EPS $0.13 Beats $(0.68) Estimate, Sales $14.344M Beat $5.843M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.68) by 119.26 percent. This is a 103.02 percent increase over losses of $(4.30) per
11-15 05:11
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
<p>Verrica Pharmaceuticals announced new data from its Phase 2 study of VP-315, an oncolytic peptide immunotherapy, demonstrating its potential to treat basal cell carcinoma (BCC). The study showed VP-315 reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells. It achieved a 97% objective response rate and 51% complete histologic clearance rate, with no severe adverse event...
11-10 13:00
Verrica Pharmaceuticals Gets European Medicines Agency's Committee's Positive Feedback To File Marketing Authorization Application For YCANTH To Treat Molluscum Contagiosum
Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the
10-21 04:09
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
The European Medicines Agency's CHMP has supported Verrica Pharmaceuticals' plan to submit a Marketing Authorization Application (MAA) for YCANTH® in the EU, based on successful Phase 3 studies in the U.S. and Japan. No additional Phase 3 trials are required. YCANTH, a cantharidin-based treatment for molluscum contagiosum, is already approved in the U.S. for adults and children aged two and older. Verrica plans to initiate regulatory submission a...
10-20 20:05
Verrica Pharmaceuticals To Present Phase 2 Data On VP-315 For Basal Cell Carcinoma At SITC 2025 Annual Meeting
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting
10-08 04:08
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Verrica Pharmaceuticals will present VP-315, an investigational oncolytic peptide for basal cell carcinoma, at the SITC 40th Annual Meeting. Both oral and poster presentations will discuss Phase 2 trial results assessing local immune activation post-treatment. The oral presentation is on November 5-9, 2025, in Maryland, with a 12:46–12:54 p.m. ET slot. VP-315, which induces immunogenic cell death, has shown promising immune responses in trials an...
10-07 20:05
